Immunosuppression in Solid-Organ Transplantation: Essentials and Practical Tips

A multidisciplinary team approach is essential for successful management of patients with solid-organ transplant. Transplant nursing encompasses care and support of transplant recipients as well as caregivers and organ donors through all phases of transplantation, from pretransplant evaluation to posttransplant recovery and maintenance. The field of solid-organ transplantation has advanced rapidly, and new treatments continue to emerge. Nurses who are responsible for the care of transplant recipients should have a knowledge base in transplant immunology and pharmacology. This review discusses mechanism of action, indication, side effects, and drug interactions of commonly used immunosuppressive medications in solid-organ transplantation. Nonoral routes of drug administration, therapeutic drug monitoring, and patient monitoring strategies are also included as practical tips for bedside nurses who are responsible for delivery of direct patient care and education of patients and their caregivers. This review focuses on the following medications: antithymocyte globulins, basiliximab, alemtuzumab, corticosteroids, tacrolimus, cyclosporine, azathioprine, mycophenolate mofetil/mycophenolate sodium, sirolimus, everolimus, belatacept, intravenous immunoglobulin, and rituximab.

[1]  A. Henning,et al.  New‐Onset Diabetes After Transplantation: Results From a Double‐Blind Early Corticosteroid Withdrawal Trial , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  Jeong M. Park,et al.  Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients. , 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[3]  C. Doligalski,et al.  Sublingual Administration of Tacrolimus: Current Trends and Available Evidence , 2014, Pharmacotherapy.

[4]  J. Gaynor,et al.  Randomized Trial of Three Induction Antibodies in Kidney Transplantation: Long-Term Results , 2014, Transplantation.

[5]  D. Rush,et al.  Banff 2013 Meeting Report: Inclusion of C4d‐Negative Antibody‐Mediated Rejection and Antibody‐Associated Arterial Lesions , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  A. Israni,et al.  OPTN/SRTR 2012 Annual Data Report: Liver , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  V. Hadjianastassiou,et al.  Rituximab in renal transplantation , 2013, Transplant international : official journal of the European Society for Organ Transplantation.

[8]  R. Lee,et al.  Current trends in immunosuppressive therapies for renal transplant recipients. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[9]  D. Leeser,et al.  Induction Therapy in Renal Transplant Recipients , 2012 .

[10]  Junchao Cai,et al.  Induction Immunosuppression Improves Long-Term Graft and Patient Outcome in Organ Transplantation: An Analysis of United Network for Organ Sharing Registry Data , 2010, Transplantation.

[11]  Klemens Budde,et al.  Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk , 2010, Transplant international : official journal of the European Society for Organ Transplantation.

[12]  L. Rostaing,et al.  A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  J. Campistol,et al.  A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  L. Rostaing,et al.  Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidney‐Transplant Patients , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  E. Woodle,et al.  A Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Comparing Early (7 Day) Corticosteroid Cessation Versus Long-Term, Low-Dose Corticosteroid Therapy , 2008, Annals of surgery.

[16]  Mark J. Thomas,et al.  Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids , 2007, Clinical transplantation.

[17]  P. Halloran,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.

[18]  E. Benedetti,et al.  Infectious complications associated with the use of rituximab for ABO‐incompatible and positive cross‐match renal transplant recipients , 2007, Clinical transplantation.

[19]  K. Hardinger,et al.  Rabbit Antithymocyte Globulin Induction Therapy in Adult Renal Transplantation , 2006, Pharmacotherapy.

[20]  D. Stablein,et al.  Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. , 2004, Journal of the American Society of Nephrology : JASN.

[21]  R. Wolfe,et al.  Chronic renal failure after transplantation of a nonrenal organ. , 2003, The New England journal of medicine.

[22]  M. Marvin,et al.  Administration of rabbit antithymocyte globulin (thymoglobulin) in ambulatory renal-transplant patients , 2003, Transplantation.

[23]  J. Fink,et al.  Peripheral administration of thymoglobulin for induction therapy in pancreas transplantation. , 2001, Transplantation proceedings.

[24]  D. Stablein,et al.  Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group. , 1999, Transplantation.

[25]  Barbara B. Hodgson,et al.  Nurse's drug handbook , 1993 .

[26]  R. Scott,et al.  Long-Term Results , 2001 .

[27]  G. Klintmalm,et al.  The use of cyclosporin A and prednisone in cadaver kidney transplantation. , 1980, Surgery, gynecology & obstetrics.